• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886

Recent Advances in the Study of 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate (CAS: 1379366-01-4)

The compound 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate (CAS: 1379366-01-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug discovery. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, including its synthesis, biological activity, and potential therapeutic uses.

Recent studies have highlighted the role of 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate as a versatile intermediate in the synthesis of novel heterocyclic compounds. Its structural features, including the presence of bromo, chloro, and nitro substituents, make it a valuable building block for the development of pharmacologically active molecules. Researchers have successfully utilized this compound in the synthesis of pyridine-based derivatives, which exhibit promising activity against various disease targets.

In a groundbreaking study published in the Journal of Medicinal Chemistry, scientists explored the antimicrobial properties of 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate derivatives. The results demonstrated significant inhibitory effects against a range of Gram-positive and Gram-negative bacteria, including drug-resistant strains. The study also revealed that these derivatives could disrupt bacterial cell wall synthesis, offering a potential mechanism of action for their antimicrobial activity.

Another area of interest is the compound's potential application in cancer therapy. Preliminary in vitro studies have shown that certain derivatives of 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate exhibit selective cytotoxicity against cancer cell lines, while sparing normal cells. These findings suggest that further optimization of this scaffold could lead to the development of novel anticancer agents with improved efficacy and reduced side effects.

The synthesis of 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate has also been a focus of recent research. A team of chemists recently reported an efficient, scalable method for its production, which involves a series of halogenation and oxidation steps. This advancement is expected to facilitate broader access to the compound for research and development purposes.

Despite these promising developments, challenges remain in the optimization of 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate-based compounds. Issues such as solubility, stability, and pharmacokinetic properties need to be addressed to translate these findings into clinically viable therapeutics. Ongoing research is focused on structural modifications to improve these characteristics while maintaining or enhancing biological activity.

In conclusion, 5-bromo-2-chloro-4-nitropyridin-1-ium-1-olate represents a promising scaffold in medicinal chemistry with diverse potential applications. The recent studies discussed in this briefing underscore its value as a building block for drug discovery and highlight the need for continued investigation into its therapeutic potential. Future research directions may include exploring its use in combination therapies, investigating its mechanism of action in greater detail, and developing more efficient synthetic routes for its production.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)